Preclinical Potency and Safety Studies of an AAV2-Mediated Gene Therapy Vector for the Treatment of <i>MERTK</i> Associated Retinitis PigmentosaThomas J. Conlon, William W. Hauswirth, Kirsten Erger et al.|Human Gene Therapy Clinical Development|2013Cited by 95